|
1）Azuma A. Pirfenidone treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis. 2012; 6: 107-14
|
|
|
|
2）Margolin SB, Lefkowitz S. A novel pharmacologic agent for prevention and resolusion of lung fibrosis. FASEB J. 1994; 8: A382
|
|
|
|
|
|
3）Macias-Barragan J, Sandoval-Rodriguez A, Navarro-Partida J, et al. The multifaced role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair. 2010; 3; 16
|
|
|
|
|
|
4）Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol. 2008; 590: 400-8
|
|
|
|
|
|
5）横山哲也，前山隆茂，緒方彩子，他．肺胞上皮細胞のアポトーシスに対するピルフェニドンの作用．分子呼吸器病．2013; 17: 127-9
|
|
|
|
|
6）Conte E, Gili E, Fagone E, et al. Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharmacol Sci. 2014; 58: 13-9
|
|
|
|
|
|
7）Wang Y, Wu Y, Chen J, et al. Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation. Cardiology. 2013; 126: 1-11
|
|
|
|
|
|
8）Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: resulta of a prospective, open-label Phase II study. Am J Respir Crit Care Med. 1999; 159: 1061-9
|
|
|
|
|
|
9）Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlledtrial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005; 171: 1040-7
|
|
|
|
|
|
10）Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010; 35: 821-9
|
|
|
|
|
|
11）Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis （CAPACITY）: two randomized trials. Lancet. 2011; 377: 1760-9
|
|
|
|
|
|
12）King Jr TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370: 2083-92
|
|
|
|
|
|
13）Azuma A, Taguchi Y, Ogura T, et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res. 2011; 12: 143
|
|
|
|
|
|
14）Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183: 788-824
|
|
|
|
|
|
15）Xaubet A, Behr J, Bendstrup E, et al. Review of idiopathic pulmonary fibrosis diagnosis and management recommendations in Europe. Sarcoidosis Vasc Diffuse Lung Dis. 2013; 30: 249-61
|
|
|
|
|
|
16）Raghu G, Rochwerg B, Zhang Y, et al. Official ATS/ERS/JRS/ALAT clinical practice guidelines: treatment of idiopathic pulmonary fibrosis–an executive summary. Am J Respir Crit Care Med. 2015; 192: Iss2 pp e3-e19
|
|
|
|
|
|
17）Bando M, Sugiyama Y, Azuma A, et al. A prospective survey of idiopathic interstitial pneumonias in a web registry in Japan. Respir Investig. 2015; 53: 51-9
|
|
|
|
|
|
18）Bando M, Yamauchi H, Ogura T, et al. Clinical experience of long-term use of pirfenidone for idiopathic pulmonary fibrosis. Intern Med. 2015; in Press
|
|
|
|
|
|
19）Ogura T, Azuma A, Inoue Y, et al. All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. Respir Investig. 2015; 53: 232-41
|
|
|
|
|
|
20）Okuda R, Hagiwara E, Baba T, et al. Safety ane efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med. 2013; 107: 1431-7
|
|
|
|
|
|
21）Arai T, Inoue Y, Sasaki Y, et al. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Respir Investig. 2014; 52: 136-43
|
|
|
|
|
|
22）坂東政司，山内浩義，杉山幸比古．ピルフェニドン検証部会：臨床調査票を用いた重症度IVの特発性肺線維症に対するピルフェニドン使用例に関する臨床的検討．厚生労働科学研究費補助金 びまん性肺疾患に関する調査研究班．平成25年度研究報告書．2014. p. 47-52
|
|
|
|
|
|
23）Sakamoto S, Itoh T, Muramatsu Y, et al. Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis. Intern Med. 2013; 52: 2495-510
|
|
|
|
|
24）三浦由記子，斉藤武文，吾妻安良太．特発性肺線維症のピルフェニドン投与の臨床効果．呼吸．2012; 31: 808-13
|
|
|
|
|
|
25）Oltmanns U, Kahn N, Palmowski K, et al. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration. 2014; 88: 199-207
|
|
|
|
|
|
26）Valeyre D, Albera C, Bradford WZ, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology. 2014; 19: 740-7
|
|
|
|
|
|
27）Loeh B, Drakopanagiotakis F, Bandelli GP, et al. Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2015; 191: 110-3
|
|
|
|
|
|
28）Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev. 2015; 24: 58-64
|
|
|
|
|
|
29）Ohkubo H, Kunii E, Moriyama S, et al. Efficacy of combined corticosteroid and pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis after surgery for lung cancer: a case report. Respir Investig. 2015; 53: 45-7
|
|
|
|
|
|
30）Iwata T, Yoshida S, Nagato K, et al. Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis. Surg Today. 2015; 45: 1263-70
|
|
|
|
|